Tailored management of stage IIIa non-small-cell lung cancer in the era of the 8th edition of the TNM classification for lung cancer

Stage IIIA is a very heterogeneous group encompassing locally advanced disease with T3 and T4 tumors without any nodal involvement and very small T1a primary tumors with unilateral mediastinal lymphatic disease. Tailored management defines interdisciplinary management requiring board decisions, whic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Future oncology (London, England) England), 2018-03, Vol.14 (6s), p.5-11
1. Verfasser: Mueller, Michael R
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 11
container_issue 6s
container_start_page 5
container_title Future oncology (London, England)
container_volume 14
creator Mueller, Michael R
description Stage IIIA is a very heterogeneous group encompassing locally advanced disease with T3 and T4 tumors without any nodal involvement and very small T1a primary tumors with unilateral mediastinal lymphatic disease. Tailored management defines interdisciplinary management requiring board decisions, which can sometimes be difficult particularly in stage IIIa non-small-cell lung cancer (NSCLC). Lobectomy still is standard of care even for stage I NSCLC, which increasingly is implemented using minimally invasive surgical technique. On the other hand even locally extended tumors are today safely resected with low morbidity and mortality. According to the 2015 guidelines of the European Society of Thoracic Surgeons any kind of anatomical lung resection for lung cancer with curative intent has to be accompanied by formal mediastinal lymph node dissection. The transcervical route for complete bilateral mediastinal lymphadenectomy offers improved completeness of resection without the need for single lung ventilation and ideally supports the concept of minimally invasive surgery.
doi_str_mv 10.2217/fon-2017-0382
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2026420447</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2026420447</sourcerecordid><originalsourceid>FETCH-LOGICAL-c355t-bc211a0458c98a745736e67d4d1c3278c8271a71c99aa9feb5caa269d45ed43c3</originalsourceid><addsrcrecordid>eNp9kT1vFDEQhi0EIuGgpEWWaGgM_lyvSxTxcVKA5qitOe9s4mjXDvZuQc8Px8slCCFB5ZnxM-_Y8xLyXPDXUgr7ZsyJSS4s46qXD8i5sFqzXnHxsMXaOtZ1Tp-RJ7XecK6tMvwxOZOu67Qy_Tn5cYA45YIDnSHBFc6YFppHWpeW0P1-DzS1CXWGaWIBp4lOa7qiAVLAQmOiyzVSLLD1bGG_XFMc4hJzui8dPn-iYYJa4xgD_LoZc_lT5yl5NMJU8dnduSNf3787XHxkl18-7C_eXrKgjFnYMUghgGvTB9eD1caqDjs76EEEJW0femkFWBGcA3AjHk0AkJ0btMFBq6B25NVJ97bkbyvWxc-xbp-ChHmtXnLZacl1W9OOvPwLvclrSe11Xmpr2zTh5H8paY3jRjrXKHaiQsm1Fhz9bYkzlO9ecL-Z6JuJfjPRbyY2_sWd6nqccfhN37vWAHcCxnVZC9YQsa3Rn7LWEUNM-A_xn9f9qdQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2275905299</pqid></control><display><type>article</type><title>Tailored management of stage IIIa non-small-cell lung cancer in the era of the 8th edition of the TNM classification for lung cancer</title><source>PubMed Central</source><creator>Mueller, Michael R</creator><creatorcontrib>Mueller, Michael R</creatorcontrib><description>Stage IIIA is a very heterogeneous group encompassing locally advanced disease with T3 and T4 tumors without any nodal involvement and very small T1a primary tumors with unilateral mediastinal lymphatic disease. Tailored management defines interdisciplinary management requiring board decisions, which can sometimes be difficult particularly in stage IIIa non-small-cell lung cancer (NSCLC). Lobectomy still is standard of care even for stage I NSCLC, which increasingly is implemented using minimally invasive surgical technique. On the other hand even locally extended tumors are today safely resected with low morbidity and mortality. According to the 2015 guidelines of the European Society of Thoracic Surgeons any kind of anatomical lung resection for lung cancer with curative intent has to be accompanied by formal mediastinal lymph node dissection. The transcervical route for complete bilateral mediastinal lymphadenectomy offers improved completeness of resection without the need for single lung ventilation and ideally supports the concept of minimally invasive surgery.</description><identifier>ISSN: 1479-6694</identifier><identifier>EISSN: 1744-8301</identifier><identifier>DOI: 10.2217/fon-2017-0382</identifier><identifier>PMID: 29664358</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Biopsy ; Cancer therapies ; Chemotherapy ; Classification ; Decision making ; Interdisciplinary aspects ; Laparoscopy ; Lung cancer ; Lymphatic system ; Medical prognosis ; Metastasis ; Minimally invasive surgery ; Patients ; stage IIIa NSCLC ; Surgery ; Systematic review ; tailored management ; thoracic surgery ; tumor board ; Tumors ; Ultrasonic imaging ; VAMLA</subject><ispartof>Future oncology (London, England), 2018-03, Vol.14 (6s), p.5-11</ispartof><rights>2018 Future Medicine Ltd</rights><rights>Copyright Future Medicine Ltd Mar 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c355t-bc211a0458c98a745736e67d4d1c3278c8271a71c99aa9feb5caa269d45ed43c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29664358$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mueller, Michael R</creatorcontrib><title>Tailored management of stage IIIa non-small-cell lung cancer in the era of the 8th edition of the TNM classification for lung cancer</title><title>Future oncology (London, England)</title><addtitle>Future Oncol</addtitle><description>Stage IIIA is a very heterogeneous group encompassing locally advanced disease with T3 and T4 tumors without any nodal involvement and very small T1a primary tumors with unilateral mediastinal lymphatic disease. Tailored management defines interdisciplinary management requiring board decisions, which can sometimes be difficult particularly in stage IIIa non-small-cell lung cancer (NSCLC). Lobectomy still is standard of care even for stage I NSCLC, which increasingly is implemented using minimally invasive surgical technique. On the other hand even locally extended tumors are today safely resected with low morbidity and mortality. According to the 2015 guidelines of the European Society of Thoracic Surgeons any kind of anatomical lung resection for lung cancer with curative intent has to be accompanied by formal mediastinal lymph node dissection. The transcervical route for complete bilateral mediastinal lymphadenectomy offers improved completeness of resection without the need for single lung ventilation and ideally supports the concept of minimally invasive surgery.</description><subject>Biopsy</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Classification</subject><subject>Decision making</subject><subject>Interdisciplinary aspects</subject><subject>Laparoscopy</subject><subject>Lung cancer</subject><subject>Lymphatic system</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Minimally invasive surgery</subject><subject>Patients</subject><subject>stage IIIa NSCLC</subject><subject>Surgery</subject><subject>Systematic review</subject><subject>tailored management</subject><subject>thoracic surgery</subject><subject>tumor board</subject><subject>Tumors</subject><subject>Ultrasonic imaging</subject><subject>VAMLA</subject><issn>1479-6694</issn><issn>1744-8301</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp9kT1vFDEQhi0EIuGgpEWWaGgM_lyvSxTxcVKA5qitOe9s4mjXDvZuQc8Px8slCCFB5ZnxM-_Y8xLyXPDXUgr7ZsyJSS4s46qXD8i5sFqzXnHxsMXaOtZ1Tp-RJ7XecK6tMvwxOZOu67Qy_Tn5cYA45YIDnSHBFc6YFppHWpeW0P1-DzS1CXWGaWIBp4lOa7qiAVLAQmOiyzVSLLD1bGG_XFMc4hJzui8dPn-iYYJa4xgD_LoZc_lT5yl5NMJU8dnduSNf3787XHxkl18-7C_eXrKgjFnYMUghgGvTB9eD1caqDjs76EEEJW0femkFWBGcA3AjHk0AkJ0btMFBq6B25NVJ97bkbyvWxc-xbp-ChHmtXnLZacl1W9OOvPwLvclrSe11Xmpr2zTh5H8paY3jRjrXKHaiQsm1Fhz9bYkzlO9ecL-Z6JuJfjPRbyY2_sWd6nqccfhN37vWAHcCxnVZC9YQsa3Rn7LWEUNM-A_xn9f9qdQ</recordid><startdate>20180301</startdate><enddate>20180301</enddate><creator>Mueller, Michael R</creator><general>Future Medicine Ltd</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EHMNL</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20180301</creationdate><title>Tailored management of stage IIIa non-small-cell lung cancer in the era of the 8th edition of the TNM classification for lung cancer</title><author>Mueller, Michael R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c355t-bc211a0458c98a745736e67d4d1c3278c8271a71c99aa9feb5caa269d45ed43c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Biopsy</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Classification</topic><topic>Decision making</topic><topic>Interdisciplinary aspects</topic><topic>Laparoscopy</topic><topic>Lung cancer</topic><topic>Lymphatic system</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Minimally invasive surgery</topic><topic>Patients</topic><topic>stage IIIa NSCLC</topic><topic>Surgery</topic><topic>Systematic review</topic><topic>tailored management</topic><topic>thoracic surgery</topic><topic>tumor board</topic><topic>Tumors</topic><topic>Ultrasonic imaging</topic><topic>VAMLA</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mueller, Michael R</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>UK &amp; Ireland Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Future oncology (London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mueller, Michael R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tailored management of stage IIIa non-small-cell lung cancer in the era of the 8th edition of the TNM classification for lung cancer</atitle><jtitle>Future oncology (London, England)</jtitle><addtitle>Future Oncol</addtitle><date>2018-03-01</date><risdate>2018</risdate><volume>14</volume><issue>6s</issue><spage>5</spage><epage>11</epage><pages>5-11</pages><issn>1479-6694</issn><eissn>1744-8301</eissn><abstract>Stage IIIA is a very heterogeneous group encompassing locally advanced disease with T3 and T4 tumors without any nodal involvement and very small T1a primary tumors with unilateral mediastinal lymphatic disease. Tailored management defines interdisciplinary management requiring board decisions, which can sometimes be difficult particularly in stage IIIa non-small-cell lung cancer (NSCLC). Lobectomy still is standard of care even for stage I NSCLC, which increasingly is implemented using minimally invasive surgical technique. On the other hand even locally extended tumors are today safely resected with low morbidity and mortality. According to the 2015 guidelines of the European Society of Thoracic Surgeons any kind of anatomical lung resection for lung cancer with curative intent has to be accompanied by formal mediastinal lymph node dissection. The transcervical route for complete bilateral mediastinal lymphadenectomy offers improved completeness of resection without the need for single lung ventilation and ideally supports the concept of minimally invasive surgery.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>29664358</pmid><doi>10.2217/fon-2017-0382</doi><tpages>7</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1479-6694
ispartof Future oncology (London, England), 2018-03, Vol.14 (6s), p.5-11
issn 1479-6694
1744-8301
language eng
recordid cdi_proquest_miscellaneous_2026420447
source PubMed Central
subjects Biopsy
Cancer therapies
Chemotherapy
Classification
Decision making
Interdisciplinary aspects
Laparoscopy
Lung cancer
Lymphatic system
Medical prognosis
Metastasis
Minimally invasive surgery
Patients
stage IIIa NSCLC
Surgery
Systematic review
tailored management
thoracic surgery
tumor board
Tumors
Ultrasonic imaging
VAMLA
title Tailored management of stage IIIa non-small-cell lung cancer in the era of the 8th edition of the TNM classification for lung cancer
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T09%3A01%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tailored%20management%20of%20stage%20IIIa%20non-small-cell%20lung%20cancer%20in%20the%20era%20of%20the%208th%20edition%20of%20the%20TNM%20classification%20for%20lung%20cancer&rft.jtitle=Future%20oncology%20(London,%20England)&rft.au=Mueller,%20Michael%20R&rft.date=2018-03-01&rft.volume=14&rft.issue=6s&rft.spage=5&rft.epage=11&rft.pages=5-11&rft.issn=1479-6694&rft.eissn=1744-8301&rft_id=info:doi/10.2217/fon-2017-0382&rft_dat=%3Cproquest_cross%3E2026420447%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2275905299&rft_id=info:pmid/29664358&rfr_iscdi=true